Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 225

1.

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

Catton CN, Lukka H, Gu CS, Martin JM, Supiot S, Chung PW, Bauman GS, Bahary JP, Ahmed S, Cheung P, Tai KH, Wu JS, Parliament MB, Tsakiridis T, Corbett TB, Tang C, Dayes IS, Warde P, Craig TK, Julian JA, Levine MN.

J Clin Oncol. 2017 Mar 15:JCO2016717397. doi: 10.1200/JCO.2016.71.7397. [Epub ahead of print]

PMID:
28296582
2.

A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.

Laurie SA, Hao D, Leighl NB, Goffin J, Khomani A, Gupta A, Addison CL, Bane A, Seely J, Filion ML, Pond GR, Levine MN.

Lung Cancer. 2017 Feb;104:65-69. doi: 10.1016/j.lungcan.2016.12.004.

PMID:
28213002
3.

The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures.

Cockburn JG, Hallett RM, Gillgrass AE, Dias KN, Whelan T, Levine MN, Hassell JA, Bane A.

BMC Cancer. 2016 Jul 28;16:555. doi: 10.1186/s12885-016-2501-0.

4.

Positron Emission Tomography-Computed Tomography (PET-CT) Versus No PET-CT in the Management of Potentially Resectable Colorectal Cancer Liver Metastases: Cost Implications of a Randomized Controlled Trial.

Serrano PE, Gafni A, Gu CS, Gulenchyn KY, Julian JA, Law C, Hendler AL, Moulton CA, Gallinger S, Levine MN.

J Oncol Pract. 2016 Jul;12(7):e765-74. doi: 10.1200/JOP.2016.011676.

PMID:
27328792
5.

A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial.

Spears M, Lyttle N, D'Costa A, Chen BE, Yao CQ, Boutros PC, Burnell M, Levine MN, O'Brien P, Shepherd L, Bartlett JM.

Oncotarget. 2016 Aug 2;7(31):49099-49106. doi: 10.18632/oncotarget.8542.

6.

Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario.

Levine MN, Julian JA, Bedard PL, Eisen A, Trudeau ME, Higgins B, Bordeleau L, Pritchard KI.

J Clin Oncol. 2016 Apr 1;34(10):1065-71. doi: 10.1200/JCO.2015.62.8503.

PMID:
26598746
7.

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study.

Addison CL, Pond GR, Cochrane B, Zhao H, Chia SK, Levine MN, Clemons M.

J Bone Oncol. 2015 Jun 12;4(2):47-53. doi: 10.1016/j.jbo.2015.04.001.

8.

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Whelan TJ, Olivotto IA, Levine MN.

N Engl J Med. 2015 Nov 5;373(19):1878-9. doi: 10.1056/NEJMc1510505. No abstract available.

9.

A Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation for Patients With Non-Small-Cell Lung Cancer.

Swaminath A, Wright JR, Tsakiridis TK, Ung YC, Pond GR, Sur R, Corbett TB, Okawara G, Levine MN.

Clin Lung Cancer. 2016 Mar;17(2):142-9. doi: 10.1016/j.cllc.2015.09.008.

PMID:
26521036
10.

A four gene signature predicts benefit from anthracyclines: evidence from the BR9601 and MA.5 clinical trials.

Spears M, Yousif F, Lyttle N, Boutros PC, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JM.

Oncotarget. 2015 Oct 13;6(31):31693-701. doi: 10.18632/oncotarget.5562.

11.

TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial.

Bartlett JM, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Chen BE, Shepherd LE, Chapman JW; NCIC CTG..

Br J Cancer. 2015 Sep 1;113(5):722-8. doi: 10.1038/bjc.2015.271.

12.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes RC, Cuzick J, Dubsky P, Gnant M, Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gray R.

Lancet. 2015 Oct 3;386(10001):1341-52. doi: 10.1016/S0140-6736(15)61074-1.

13.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG)., Coleman R, Powles T, Paterson A, Gnant M, Anderson S, Diel I, Gralow J, von Minckwitz G, Moebus V, Bergh J, Pritchard KI, Bliss J, Cameron D, Evans V, Pan H, Peto R, Bradley R, Gray R.

Lancet. 2015 Oct 3;386(10001):1353-61. doi: 10.1016/S0140-6736(15)60908-4. Erratum in: Lancet. 2016 Jan 2;387(10013):30.

14.

Regional Nodal Irradiation in Early-Stage Breast Cancer.

Whelan TJ, Olivotto IA, Parulekar WR, Ackerman I, Chua BH, Nabid A, Vallis KA, White JR, Rousseau P, Fortin A, Pierce LJ, Manchul L, Chafe S, Nolan MC, Craighead P, Bowen J, McCready DR, Pritchard KI, Gelmon K, Murray Y, Chapman JA, Chen BE, Levine MN; MA.20 Study Investigators..

N Engl J Med. 2015 Jul 23;373(4):307-16. doi: 10.1056/NEJMoa1415340.

15.

(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer.

You JJ, Cline KJ, Gu CS, Pritchard KI, Dayes IS, Gulenchyn KY, Inculet RI, Dhesy-Thind SK, Freeman MA, Chan AM, Julian JA, Levine MN.

Br J Cancer. 2015 May 26;112(11):1737-43. doi: 10.1038/bjc.2015.151.

16.

Defining breast cancer intrinsic subtypes by quantitative receptor expression.

Cheang MC, Martin M, Nielsen TO, Prat A, Voduc D, Rodriguez-Lescure A, Ruiz A, Chia S, Shepherd L, Ruiz-Borrego M, Calvo L, Alba E, Carrasco E, Caballero R, Tu D, Pritchard KI, Levine MN, Bramwell VH, Parker J, Bernard PS, Ellis MJ, Perou CM, Di Leo A, Carey LA.

Oncologist. 2015 May;20(5):474-82. doi: 10.1634/theoncologist.2014-0372.

17.

A survivorship care plan for breast cancer survivors: extended results of a randomized clinical trial.

Boekhout AH, Maunsell E, Pond GR, Julian JA, Coyle D, Levine MN, Grunfeld E; FUPII Trial Investigators..

J Cancer Surviv. 2015 Dec;9(4):683-91. doi: 10.1007/s11764-015-0443-1.

PMID:
25896265
18.

Prognostic associations of 25 hydroxy vitamin D in NCIC CTG MA.21, a phase III adjuvant randomized clinical trial of three chemotherapy regimens in high-risk breast cancer.

Lohmann AE, Chapman JA, Burnell MJ, Levine MN, Tsvetkova E, Pritchard KI, Gelmon KA, O'Brien P, Han L, Rugo HS, Albain KS, Perez EA, Vandenberg TA, Chalchal HI, Sawhney RP, Shepherd LE, Goodwin PJ.

Breast Cancer Res Treat. 2015 Apr;150(3):605-11. doi: 10.1007/s10549-015-3355-x.

PMID:
25833209
19.

Predictors of adverse cosmetic outcome in the RAPID trial: an exploratory analysis.

Peterson D, Truong PT, Parpia S, Olivotto IA, Berrang T, Kim DH, Kong I, Germain I, Nichol A, Akra M, Roy I, Reed M, Fyles A, Trotter T, Perera F, Balkwill S, Lavertu S, Elliott E, Julian JA, Levine MN, Whelan TJ; RAPID trial investigators..

Int J Radiat Oncol Biol Phys. 2015 Apr 1;91(5):968-76. doi: 10.1016/j.ijrobp.2014.12.040.

PMID:
25832689
20.

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014.

Lyman GH, Bohlke K, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, Clarke JM, Flowers CR, Francis CW, Gates LE, Kakkar AK, Key NS, Levine MN, Liebman HA, Tempero MA, Wong SL, Somerfield MR, Falanga A; American Society of Clinical Oncology..

J Clin Oncol. 2015 Feb 20;33(6):654-6. doi: 10.1200/JCO.2014.59.7351.

Supplemental Content

Loading ...
Support Center